13.10
0.69%
0.09
Handel nachbörslich:
13.10
Takeda Pharmaceutical Co Adr Aktie (TAK) Neueste Nachrichten
Weekly Upgrades and Downgrades - InvestorPlace
Cancer Monoclonal Antibodies Market to Grow at a 18.4% CAGR through 2031 | SkyQuest Technology - Benzinga
Saudi Arabia Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Dr. Kevan Jacobson and Dr. Genelle Lunken Awarded $1M Pioneer Grant for Transformative Pediatric Research in Inflammatory Bowel Disease - Quantisnow
Things To Consider Before You Buy Takeda Pharmaceutical Co ADR (NYSE: TAK) - Stocks Register
Capital One Financial Corp (NYSE: COF): Overvalued In Comparison To Others? - Stocks Register
Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies - MSN
Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform - Quantisnow
Australia Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Denmark Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Italy Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
UK Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
South Africa Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.
Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading - MSN
Earnings call: Takeda reports robust H1 growth, revises full-year guidance - Investing.com Australia
Earnings call: Takeda reports robust H1 growth, revises full-year guidance By Investing.com - Investing.com South Africa
Torm Plc (NASDAQ: TRMD): Getting A Free Pass? - Stocks Register
What Analysts Were Expecting After Checkpoint Therapeutics Inc (NASDAQ: CKPT) rose 2.03% - Stocks Register
Spain Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Thailand Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Dyne Therapeutics Inc (DYN) gets rating Reiterated from Chardan Capital Markets - Knox Daily
W & T Offshore Inc (WTI) receives a Buy rating from Stifel - Knox Daily
JP Morgan Upgrades Mister Car Wash Inc (MCW) to an Overweight from a Neutral - Knox Daily
BofA Securities upgrades Takeda Pharmaceutical Co ADR (TAK) rating to a Buy - Knox Daily
What Did We Find About Insider Trading At Ovintiv Inc (NYSE: OVV)? - Stocks Register
Mizuho analysts downgrades a Neutral rating for Squarespace Inc (SQSP) - Knox Daily
Barclays gives an Equal weight recommendation for Kilroy Realty Corp. (KRC) - Knox Daily
Microchip Technology, Inc. (MCHP) receives a Hold rating from Truist - Knox Daily
Cantor Fitzgerald’s latest rating for EBAY stock - Knox Daily
Watch this stock’s price performance: Takeda Pharmaceutical Co ADR (NYSE:TAK) - US Post News
North America Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research
Mexico Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research
China Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research
Italy Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research
Checking in on Takeda Pharmaceutical Co ADR (TAK) after recent insiders movement - Knox Daily
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):